All posts by imreal

Life Molecular Imaging and BIOKOSMOS SA Announce a Strategic Partnership for the Production and Supply of Neuraceq® in Greece, Bulgaria, North Macedonia and Albania


Life Molecular Imaging / BIOKOSMOS

Our strategic partnership with LMI will expand the availability of the innovative molecular imaging agent Neuraceq®, to patients of the wider Balkan region

Life Molecular Imaging (LMI) and BIOKOSMOS SA announced today that both companies have entered into a strategic partnership and licensing agreement providing BIOKOSMOS with rights to manufacture and distribute Neuraceq® in Greece, Bulgaria, North Macedonia and Albania.

BIOKOSMOS SA will start manufacturing Neuraceq® in their manufacturing sites in Athens and Thessaloniki, Greece, as soon as the necessary authorisations from the relevant authorities have been obtained.

Neuraceq® is an approved imaging agent for the detection of beta-amyloid plaques in the brain that is used in clinical routine. It is also a powerful imaging biomarker for the appropriate characterisation of subjects enrolled in clinical trials to support drug development in neurodegenerative diseases.

“With the addition of four countries, Life Molecular Imaging continues to expand the availability of Neuraceq®, an important diagnostic imaging tool for the detection of beta-amyloid plaques in the brain. We are truly excited about this collaboration with BIOKOSMOS to make our approved amyloid tracer Neuraceq® even more available to physicians and our pharma partners for routine clinical and research use” said Ludger Dinkelborg, Ph.D., Managing Director at LMI.

“It is a great pleasure to have signed this important manufacturing and distribution agreement with Life Molecular Imaging” – declares Angelos Pagonis, President of the Board and CEO at BIOKOSMOS. “Our strategic partnership with LMI will expand the availability of the innovative molecular imaging agent Neuraceq®, to patients of the wider Balkan region, contributing to the fight against Alzheimer’s disease and other causes of cognitive decline”.

About Neuraceq (florbetaben 18F)

Indication

Neuraceq® is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline.

A negative Neuraceq® scan indicates sparse to no amyloid neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq® scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq® is an adjunct to other diagnostic evaluations.

Limitations of Use

  • A positive Neuraceq® scan does not establish the diagnosis of AD or any other cognitive disorder.
  • Safety and effectiveness of Neuraceq® have not been established for (i) predicting development of dementia or other neurologic conditions and (ii) monitoring responses to therapies.

Important Safety Information

Risk for Image Interpretation and Other Errors

Neuraceq® can be used to estimate the density of beta-amyloid neuritic plaque deposition in the brain. Neuraceq® is an adjunct to other diagnostic evaluations. Neuraceq® images should be interpreted independent of a patient’s clinical information. Physicians should receive training prior to interpretation of Neuraceq® images. Following training, image reading errors (especially false positives) may still occur. Additional interpretation errors may occur due to, but not limited to, motion artifacts or extensive brain atrophy.

Radiation Risk

Administration of Neuraceq®, like other radiopharmaceuticals, contributes to a patient´s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. It is important to ensure safe handling to protect patients and health care workers from unintentional radiation exposure.

Most Common Adverse Reactions

In clinical trials, the most frequently observed adverse drug reactions in 1077 subjects with 1295 Neuraceq® administrations were injection/application site erythema (1.4%), and injection site pain (3.1%).

About Life Molecular Imaging (LMI)

Life Molecular Imaging (LMI, formerly Piramal Imaging) was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. It is now part of the Alliance Medical Group (a member of the Life Healthcare Group) offering an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. By developing novel PET tracers for molecular imaging, LMI is focusing on a key field of modern medicine. The organization strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. Please visit https://life-mi.com.

About Life Healthcare Group

Life Healthcare is a global people-centered, diversified healthcare organization listed on the Johannesburg Stock Exchange. Life Healthcare has over 38 years’ experience in the South African private healthcare sector, and currently operates 66 healthcare facilities in southern Africa. Services include acute hospital care, acute physical rehabilitation, acute mental healthcare, renal dialysis, and wellness, occupational health, primary health and emergency medical services. The Group owns Alliance Medical Group, the leading independent provider of medical imaging services (MRI, CT and PET scans) within Europe, operating internationally across 10 countries. Life Molecular Imaging, a division of Alliance is an integrated pharmaceutical business that includes research and development laboratories, access to a network of cyclotrons and radio-pharmacies and imaging facilities, with Life Radiopharma being Alliance’s distributor of radiopharmaceuticals to diagnose many types of diseases. Visit https://www.lifehealthcare.co.za/

About BIOKOSMOS SA

BIOKOSMOS SA was founded in 1992, providing high level services and solutions in the field of Nuclear Medicine and Oncology. Today, BIOKOSMOS is a key radiopharmaceutical manufacturer with two manufacturing sites in Greece, one in Athens and the other in Thessaloniki, and has established a comprehensive distribution network, fully covering the needs of the wider Balkan region for innovative radiopharmaceuticals in Molecular Imaging and in Oncology.

For more information visit: https://www.biokosmos.gr/ and follow BIOKOSMOS on LinkedIn.

For media queries

Alya Schalabi | Marketing Europe | Life Molecular Imaging

Tel#: +49 151 1456 9895 | a.schalabi@life-mi.com

Share article on social media or email:

Worldwide Customer Communications Management (CCM) 2022 Vendor Assessment


Doxim logo

As a technology-enabled managed services provider, Doxim generates and delivers personalized, omnichannel communications that align with today’s customer expectations for engagement, drive increased loyalty and wallet share — Doxim CEO Mike Rogalski

Doxim, the leading customer communications management (CCM) and engagement technology provider serving regulated markets, today announced that it has been named as a Major Player in the IDC MarketScape: Worldwide Customer Communications Management (CCM) 2022 Vendor Assessment – Dynamic Delivery of Multichannel Personalized Experiences (doc #US48167722, June 2022)

The IDC MarketScape provides an assessment of 13 cloud-based customer communications management application vendors that emphasize delivery of multichannel, personalized, and interactive communications to improve the customer experience.

“We are very pleased that the IDC MarketScape has recognized Doxim as a Major Player in the IDC MarketScape Worldwide Cloud CCM vendor assessment,” said Doxim CEO Mike Rogalski. “As a technology-enabled managed services provider, Doxim generates and delivers personalized, omnichannel communications that align with today’s customer expectations for engagement, drive increased loyalty and wallet share. Our cloud-based SaaS platform delivers value by empowering business users, taking away the complexity of managing regulated communications, and helping our clients evolve their communications strategy and digitally transform, at their pace, with our feature-rich, scalable, and secure solutions.”

About IDC MarketScape:

IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of ICT (information and communications technology) suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.

About Doxim:

Doxim is the customer communications management and engagement technology leader serving highly regulated markets, including financial services, utilities and healthcare. We provide omnichannel document and payment solutions that transform experiences and strengthen engagement throughout the entire lifecycle.

The Doxim Platform helps clients communicate reliably and effectively, improves cross-sell and upsell opportunities, and drives increased loyalty and wallet share through personalized communications and easy-to-use payment processes. The platform addresses key digitization, operational efficiency, and customer experience challenges through our suite of plug-and-play, integrated, SaaS software and technology solutions. Learn more at http://www.doxim.com.

Share article on social media or email:

Due to Clinical Laboratory Services, Doctors Can Treat Patients Like Never Before


“Demand is growing because clinical laboratories are improving physicians’ ability to treat patients like never before.” – Bruce Carlson, publisher for Kalorama Information.

Clinical laboratories are an essential part of the health industry, and as a result the global market for clinical laboratory services grew to an estimated $168.3 billion in 2021 (including $79 billion generated from markets outside the United States), reveals leading medical market research firm Kalorama Information in the new report Clinical Laboratory Services Market, 7th Edition. COVID-19 testing demand increased the clinical laboratory services market by more than $31 billion over the year.

A clinical laboratory, also known as a medical laboratory, is a department within a facility (i.e., hospital) or a stand-alone facility that processes microbiological, serological chemical, hematological, immuno-hematological, immunological, toxicological, cytogenetical, exfoliative cytological, histological, pathological or other examinations from material derived from the human body.

It is estimated that between 70% – 80% of physicians’ diagnoses are a result of laboratory tests. In addition to diagnosing patients, clinical lab testing is performed to evaluate disease progression, monitor drug treatment and conditions, determine individual therapy, and for several other reasons. In oncology indications, clinical laboratory services are involved in 100% of patient care plans.

Besides the remarkable and continued growth in 2021 due to COVID-19 demand, there are a number of drivers that will affect steady growth for this market in coming years. Among these are:


  • an aging population,
  • a growing incidence of chronic diseases and management,
  • increasing emphasis on diagnosis and disease monitoring, and
  • growth in advanced laboratory testing technologies and practices.

“Demand is growing because clinical laboratories are improving physicians’ ability to treat patients like never before. There is a shift in healthcare utilization primarily due to reducing healthcare spending, which makes the laboratory an even more valuable part of the treatment plan,” says Bruce Carlson, publisher for Kalorama Information.

In efforts to reduce health-related costs, hospitals have been striving to reduce length of stays. In the U.S., this has been a primary area of focus to reduce health spending, moving procedures and care to outpatient facilities when appropriate. To continue to try and keep stays at a minimum and ultimately reduce cost, monitoring technologies, diagnostic imaging and laboratory measures and disease/treatment monitoring through diagnostic laboratory practices are primary ways physicians and administrators are continuing to meet optimal healthcare outcomes while also reducing costs.

Global markets are also feeling pressures to reduce health spending and to some degree have focused on shifting health services to outpatient and home-based locations. The length of stay on a global level is estimated at 7.2 days on average, South Korea and Japan are among the higher days of hospitalization.

“Kalorama Information’s analysts anticipate that the market will see an increase in the number of clinical laboratories, particularly in the independent and community sectors, as these trends continue to influence the industry and add pressure to clinical laboratories in an effort to reduce costs and still provide adequate healthcare,” says Carlson.

For more information about the report or to purchase Clinical Laboratory Services Market, 7th Edition, please visit: https://kaloramainformation.com/product/clinical-laboratory-service-markets-7th-edition/.

Share article on social media or email:

MIB Agents Selects OncoLens to Support and Expand its TURBO Program Globally


“For the TURBO program and global osteosarcoma community, OncoLens is helping streamline multidisciplinary clinical insights, education and access, more effectively and efficiently than ever before,” said Matteo Trucco, MD, a pediatric oncologist from Cleveland Clinic and TURBO moderator.

MIB Agents has engaged OncoLens to support the organization’s Tumor Review Board for Osteosarcoma (TURBO) program. This virtual tumor board brings together a multidisciplinary team of global osteosarcoma experts to review patient cases, share experiences, and build knowledge across the sarcoma community. OncoLens’ multidisciplinary care platform captures, shares, and tracks cases immediately and over time, providing vital data to enhance care.

Osteosarcoma is an aggressive, malignant primary bone cancer. It is the most prevalent bone cancer in the United States, with between 800-1,000 new patients diagnosed each year. Osteosarcoma is also the most prevalent bone cancer impacting children and young adults.

“TURBO brings together great minds in osteosarcoma research and care across geographies and institutions facilitating collaboration,” said Katie Janeway, MD, a pediatric oncologist at Dana-Farber Cancer Institute.

TURBO currently conducts six tumor boards annually, during which key opinion leaders, experts, and clinicians supporting osteosarcoma patients come together to discuss patient cases. In addition to supporting care planning, the program creates a network of expertise and insight that helps accelerate education, research focus areas, and grant opportunities. After a successful start in the US, MIB Agents will be expanding participation and increasing frequency to twelve times per year to include global osteosarcoma experts.

“For the TURBO program and global osteosarcoma community, OncoLens is helping streamline multidisciplinary clinical insights, education, and access, more effectively and efficiently than ever before,” said Matteo Trucco, MD, a pediatric oncologist from Cleveland Clinic and TURBO moderator. “The collaboration that we can achieve on a global scale will help physicians from across all disciplines more efficiently review cases, share available clinical trials, and promote collaboration.”

“We are proud to support the work of MIB Agents and the TURBO program,” said Anju Mathew, chief executive officer for OncoLens. “This work is another example of how a multidisciplinary cancer care platform can drive connection, collaboration, and knowledge sharing for some of the world’s most complex and difficult-to-treat cancers. We are thrilled to partner with MIB Agents and support their efforts in driving osteosarcoma research, treatment, and education.”

####

About MIB Agents

Founded in 2012, MIB Agents is a leading pediatric osteosarcoma nonprofit dedicated to making it better for our community of patients, caregivers, doctors, and researchers through programs, education, and research.

About OncoLens

OncoLens is the single platform that enables multidisciplinary cancer care across the continuum. Through a streamlined, secure HIPAA-compliant infrastructure, OncoLens drives intra-enterprise, community, network, and affiliate participation in multidisciplinary care planning, tracking, and delivery. Using OncoLens, cancer providers can capture, disseminate, and track quality, best practices, and protocols. And with direct EMR and cancer registry integration, data and abstraction are automated and accelerated. The OncoLens platform allows providers to aggregate, create and track the comprehensive patient journey across the continuum. This includes maximized clinical trial participation, an extended referral stream, and the creation of a center of excellence that can be leveraged to support patient care and provider education. With OncoLens, providers can realize and expand their reputation to increase patient-driven referrals, decrease patient leakage and enhance their brand within the oncology community. More than 200 cancer centers and associations across the U.S and internationally rely on OncoLens to support their cancer programs and the care delivered.

Share article on social media or email:

RSNA R&E Foundation Approves Over $4 Million in Grant Funding


The funding of grant recipients for over three decades demonstrates the strong and steadfast commitment of the RSNA in supporting innovation and discovery across radiology.

The Radiological Society of North America (RSNA) Research and Education (R&E) Foundation Board of Trustees has announced that they have approved over $4 million in radiology research and education grants this year, achieving a funding rate of 42% of grant applications. Since the R&E Foundation’s inception in 1984, it has awarded over $70 million in grant funding.

“Through the generosity of our donors, the RSNA R&E Foundation is able to seed the future of radiology,” said Vijay M. Rao, M.D., chair of the R&E Foundation Board of Trustees. “The Board of Trustees expresses its deep appreciation for the individuals, practice groups and corporate partners who make this support possible.”

The RSNA R&E Foundation has provided support for more than 1,600 investigators and educators and over 1,700 projects, thanks to donor support. Grant recipients have received 50 additional dollars in subsequent funding from other sources for every dollar funded by the Foundation, making the impact of that funding even greater.

The RSNA R&E Foundation is a critical source of early support for young investigators and educators. This year, the RSNA R&E Foundation will be supporting 91 individuals at 46 institutions.

“Investing in careers and driving scientific innovation are the cornerstones of our Foundation, and the Board of Trustees is honored to support the efforts of these inspiring investigators and educators,” Dr. Rao said. “The funding of grant recipients for over three decades demonstrates the strong and steadfast commitment of the RSNA in supporting innovation and discovery across radiology.”

The Board of Trustees also approved funding for five Research Medical Student Grant applicants. These applicants self-identified as a minority medical student underrepresented in medicine. This initiative—launched in 2020—was created as an entry mechanism for attracting diverse medical students to the specialty and radiology research.

This year, the Foundation launched the new R&E Education Project Award. Five educators will receive funding through the new award, which is designed to recognize and highlight the importance of radiology educators by providing supplemental funding for new or ongoing education initiatives, such as projects that promote innovative teaching methodologies, resources or delivery evaluation mechanisms.

“We are sincerely grateful to all who have invested in our Foundation,” Dr. Rao said. “This investment makes the entire specialty stronger and ensures better outcomes for the patients we serve.”

For more information about the RSNA R&E Foundation and the funded 2022 projects, visit RSNA.org/Foundation.

RSNA is an association of radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and healthcare delivery through education, research and technologic innovation. The Society is based in Oak Brook, Ill. (RSNA.org)

The mission of the R&E Foundation is to invest in the future of radiology by developing investigators and supporting lifelong innovative research and education. (RSNA.org/Foundation)

Share article on social media or email:

Nominations Open for Annual CellTrak Home Care Aide Scholarship Program


CellTrak Home Care Aide Scholarship

15 scholarships to be awarded to Home Care Aides. Call for nominations for CellTrak Home Care Aide Scholarship program.

“Home Care Aides are healthcare heroes, caring for our friends and family every day on the front lines, and we are honored to support their individual growth by helping them invest in their future.”

The call for nominations is officially open for the annual CellTrak Home Care Aide Scholarship, benefiting Aides across the country with scholarships to continue their educational efforts and further their home-based care careers. This year, the scholarship amounts have been doubled, increasing from $500 to $1,000 for 15 deserving Aides.

CellTrak, a Homecare Homebase company, the provider of the industry’s leading mobile solution used by home care aides to empower better outcomes for the home continues its annual joint scholarship program with the National Association for Home Care & Hospice (NAHC).

Most Americans want to stay in their own home as they age, according to a study released by NORC Centers for Public Affairs Research. Home Care Aides are an essential part of the support system required for many aging Americans and deserve recognition for the vital care they provide. The pandemic has helped shine a light on the importance that aides serve in keeping our aging population at home, and in their preferred care setting.

“NAHC is thrilled to continue our very successful partnership with CellTrak,” said William A. Dombi, Esq., president of NAHC. “The annual joint scholarship program has demonstrated it can help aides advance their studies and careers within home care, at a time when providers are facing greater workforce pressures than ever before. This scholarship program is needed more than ever. In addition, the scholarships give aides an opportunity to tell their caregiving stories so Americans understand the enormous difference these under-appreciated people make in the lives of so many of our most vulnerable citizens.”

November is National Home Care Month, a time to celebrate the practice of home care, and all the individuals who make it possible. Part of the months’ celebration includes one week focusing solely on home care aides. They are key to our health system transformation and the annual scholarship program gives fifteen recipients an opportunity to move forward with educational efforts within the industry.

This year, nominations can be submitted online and onsite during the Financial Management Conference hosted by NAHC. Please make sure to stop in the Marketplace booth #306 to register in person!

Andrew Kaboff, CRO (Co-founder) of CellTrak explained why the scholarship program is important to CellTrak: “We are happy to announce the kickoff of the third annual CellTrak Home Care Aide Scholarship Program and are excited to be doubling the award amount for 15 deserving recipients. Home Care Aides are healthcare heroes, caring for our friends and family every day on the front lines, and we are honored to support their individual growth by helping them invest in their future.”

This will be the third year a Home Care Aide specific scholarship program will be offered through the National Association for Home Care & Hospice. Aides awarded with scholarships will be announced in November 2022. If you are interested in nominating someone for the scholarship program, please nominate by using this link by October 1, 2022 https://www.celltrak.com/about/celltrak-scholarship.

Scott Decker, Chief Executive Officer of Homecare Homebase stated: “HCHB is proud to support the annual CellTrak Home Care Aide Scholarship. Aides make a huge difference in the lives of the people they serve, by helping with essential activities of daily living and providing much needed interaction and support to combat isolation and ensure our most fragile patients are able to receive care in the place they call ‘home’. The scholarship is a rewarding program that shows appreciation for this critical group of caregivers.”

About Homecare Homebase, LLC

Homecare Homebase is a Dallas-based software leader offering hosted, cloud-based solutions to streamline operations, simplify compliance and boost clinical and financial outcomes for home-based care agencies. Our customized mobile solutions enable real-time, wireless data exchange and communication between field clinicians, physicians and office staff for better care, more accurate reporting, and improved revenue cycle management. Founded by industry veterans in 1999, HCHB empowers over 200,000 users to service more than 800,000 patients daily, resulting in over one hundred million visits per year. The company is part of the Hearst Health network. For more information visit http://www.hchb.com or call us toll-free at 1- 866-535-HCHB (4242)

CellTrak

CellTrak, a Homecare Homebase Company, is used by leading providers from home care, hospice and behavioral health agencies, offers a mobile app, interactive voice response (IVR) system, and web portal that uniquely includes data analytics and real-time messaging to give providers the ability to manage, monitor and connect with field caregivers to improve outcomes. Over 500 million visits have been electronically verified by CellTrak across the US, UK, and Canada by over 130,000 caregivers. CellTrak’s strategic partnerships with the leading EMRs and EVV aggregators allows for easy implementations and delivery of the best of breed solutions in the industry. For more information, visit http://www.celltrak.com.

About Hearst Health

The mission of Hearst Health is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person’s health journey. Care guidance from Hearst Health reaches the majority of people in the U.S. The Hearst Health network includes FDB (First Databank), Zynx Health, MCG, Homecare Homebase and MHK (formerly MedHOK). Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen. Follow Hearst Health on Twitter @HearstHealth and LinkedIn @Hearst-Health.

EMRs and EVV aggregators allows for easy implementations and delivery of the best of breed solutions in the industry. For more information, visit http://www.celltrak.com.

About National Association for Home Care & Hospice (NAHC)

The National Association for Home Care & Hospice (NAHC) is the voice of home care and hospice. NAHC represents the nation’s 33,000 home care and hospice providers, along with the more than two million nurses, therapists, and aides they employ. These caregivers provide vital services to Americans who are aged, disabled, and ill. Some 12 million patients depend on home care and hospice providers, who depend on NAHC for the best in advocacy, education, and information. NAHC is a nonprofit organization that helps its members maintain the highest standards of care. To learn more, visit nahc.org.

Share article on social media or email:



Robotic Surgery Pioneer, Dr. Danny Shouhed, is the Country’s First Surgeon to Perform Bariatric Surgery with Completely Hidden Incisions


News Image

“Today, there are more options than ever for weight loss. The hidden incision robotic sleeve gastrectomy is truly a game changer for the patients that qualify because it minimizes scarring, has a faster recovery time, and allows patients to keep their surgery confidential,” said Dr. Danny Shouhed.

The sleeve gastrectomy is the most common bariatric procedure performed around the world. It involves resecting 70-80% of the stomach, leading to restriction, decreased hunger, and increased satiety through hormonal changes in the gut. The surgery is typically performed laparoscopically with 3-6 incisions that are seen across the abdomen. Dr. Shouhed has performed the procedure for a handful of select patients with three incisions hidden beneath the patient’s waistline. Unlike a traditional robotic sleeve gastrectomy, where small incisions are made near a patient’s belly button, this minimally invasive technique differs by placing incisions below the waistline, allowing the small scars to remain hidden from view when patients wear jeans or a bathing suit.

“It’s similar to a C-section scar since they are so low. It gives patients an opportunity to keep their surgery confidential. A lot of patients don’t want people to know they had bariatric surgery to lose weight, so this technique makes it possible for them to hide their procedure,” said Dr. Shouhed.

With the more common techniques, micro-incisions near the abdomen can still be visible to the naked eye, and Single Incision Laparoscopic Surgery (SILS) – a procedure that creates a single, larger incision in the belly button – may lead to higher hernia and complication rates for patients.

“Today, there are more options than ever for weight loss. The hidden incision robotic sleeve gastrectomy is truly a game changer for the patients that qualify because it minimizes scarring, has a faster recovery time, and allows patients to keep their surgery confidential,” said Dr. Danny Shouhed.

Unfortunately, not every patient is a candidate for this procedure. Due to the limitations of the robotic instruments, the “invisible” procedure can only be performed on patients who are of average height and who are not extremely obese. This is because the tools may not safely reach the surgery site.

**For Spanish-language media: Dr. Danny Shouhed conducts interviews in Spanish.

About Dr. Danny Shouhed:

Dr. Danny Shouhed is a board-certified and top robotic general surgeon in Los Angeles. He is a renowned expert in gastrointestinal, metabolic, and bariatric surgical intervention, training many of his colleagues in complex techniques. His specialties include gastric sleeve, gastric bypass, revision bariatric surgery, hernia repair, spleen and gallbladder surgery, colon and small intestine disorders, appendix removal and GI cancer surgery. To learn more about Dr. Danny Shouhed’s practice and his professional services, please visit: https://www.drdannyshouhed.com.

Share article on social media or email:

Sacrix LLC highlights its patented sacroiliac joint screw and technique in the face of competitor copying


Sacrix’s patented screw design with cortical threads adjacent to cancellous threads plus fusion channels

“Sacrix has noticed that many companies have now copied our design of the cortical and cancellous threads with a channel and 3D porous structure which are covered by the Patent US 11,129,655” says Professor Dr. Kingsley R Chin.

Sacrix’s sacrofuse has a unique design and technique and was issued a United States patent on September 28th, 2021. Sacrix highlights two important claims.

Key Patented Claims

We received patent protection on our design having cortical threads adjacent to cancellous threads plus fusion channels. This is a significant claim since the anatomy and trajectory require differential threads and self-harvesting bone channels. We note companies copying these features.

1. A bone fusing implant device comprising: an elongated body extending along a longitudinal direction; wherein the elongated body comprises a first segment having an outer surface with cortical threads, a second segment having an outer surface with cancellous threads, a top segment and a bottom segment; wherein the first segment is adjacent to the second segment along the longitudinal direction and is configured to engage a cortical bone with the cortical threads and the second segment is configured to engage a cancellous bone with the cancellous threads; wherein the elongated body comprises one or more elongated fusing gutters extending along the longitudinal direction on an outer surface of the elongated body covering the first and second segments, a central opening extending along the longitudinal direction through the elongated body’s center and one or more through openings that extend horizontally and intersect with the one or more fusing gutters; wherein the cortical threads are more closely spaced than the cancellous threads.

This is an important claim to protect our 3D porous structure design.

2. The device of claim 1, wherein the elongated fusing gutters comprise a trabecular lattice structure and do not cut through the cortical threads and the cancellous threads.

“We focus on innovating surgical techniques, instrumentation and ultimately the implanted device. Our granted patent is a testament to the innovation we intend to enforce and maintain our ability to improve patient care” said Vito Lore, VP of Innovation

“Sacrix has noticed that many companies have now copied our design of the cortical and cancellous threads with a channel and 3D porous structure which are covered by the Patent US 11,129,655,” said Co-Inventor Dr Kingsley R. Chin, a Professor and Board-Certified Orthopedic Spine Surgeon and interim-acting CEO of Sacrix LLC. “This is a serious matter that has our focused attention”

We believe innovation is better for patient care and copying sets back the industry. Our competitors should focus on innovating to push the field forward. The Sacrix percutaneous lateral-oblique technique uses two steps under 100% fluoroscopy, no open incision, and is a perfect complement to the screw design for sacroiliac joint fixation. There is no need for drilling or tapping, even in patients with advanced osteoporosis and no device-related failure with clinical use so far. The 3D porous thread design and channel for fusion are significant advances in sacroiliac joint fixation over competitive products such as SI-Bone TTI and other partially threaded screws in the market.

About Sacrix LLC

Sacrix LLC is a KICVentures Group portfolio company focused on revolutionary percutaneous fluoroscopic lateral-oblique sacroiliac joint fusion technologies for the treatment of sacroiliac dysfunction and sacroiliitis. Sacrix developed its patented Sacrofuse threaded implant to be inserted percutaneously and received FDA clearance in 2015. The Gen1 Sacrofuse implant was compared head-to-head with market leader SI bone (SIBN) and found to have a 400% increase in pull-out strength. Sacrix has trained over 165 interventional pain physicians to perform its revolutionary percutaneous lateral-oblique sacroiliac joint fusion technique safely and effectively through a 1.5 cm incision minimally invasively in outpatient ambulatory surgery centers.

http://www.MySacrix.com

About KICVentures Group

Founded in 2000 makes us the most experienced healthcare investment holding company with the largest portfolio of medical device technologies focused on solutions for less invasive outpatient spine surgery. Our investment strategy is to acquire or invent disruptive technologies using our own capital or partner with private individual investors. This allows us the freedom to make quick and nimble decisions such as when we acquired AxioMed Viscoelastic Disc Technologies while other firms invested in ball-and-socket articulating spacers.

http://www.KICVentures.com

Share article on social media or email:

Vertical Flight Society Announces Winner of 2022 Alfred Gessow Best Paper Award


VFS awarded the prestigious 2022 Alfred Gessow Award to Dr. Christina Ivler, University of Portland, lead author of “Toward a UAS Handling Qualities Specification: Development of UAS-Specific MTEs.”

VFS awarded the prestigious 2022 Alfred Gessow Award to Dr. Christina Ivler, University of Portland, lead author of “Toward a UAS Handling Qualities Specification: Development of UAS-Specific MTEs.”

This year’s Forum 78 was held in May in Fort Worth, Texas. As the Forum 78 Alfred Gessow Best Paper Award winner, Dr. Ivler will present the paper at the 48th Annual European Rotorcraft Forum (ERF) on Sept. 7, 2022, in Winterthur, Switzerland.

The Vertical Flight Society (VFS) announced today the winner of the Society’s prestigious Alfred Gessow Award for the best overall technical paper presented at the 78th Annual Forum and Technology Display. This year’s winning paper is from the Handling Qualities session entitled, “Toward a UAS Handling Qualities Specification: Development of UAS-Specific MTEs,” by Dr. Christina Ivler and Kate Russell of the University of Portland; and Drs. Anthony Gong, Tom Berger and Mark J.S. Lopez of US Army Combat Capabilities Development Command (DEVCOM) Aviation and Missile Center (AvMC).

Dr. Ivler is an assistant professor of mechanical engineering at the University of Portland. Her research interests are in rotorcraft system identification, control and handling qualities. She received her B.S. and M.S. degrees from the University of California Davis and her doctorate in Aeronautics and Astronautics from Stanford University. The winning Forum 78 paper highlighted key outcomes of the University of Portland’s unmanned aircraft systems (UAS), including proposed UAS-specific maneuvers as mission task elements (MTEs), the validation of performance specifications, and validation of the Froude-scaled ADS-33E-PRF Level 1 attitude bandwidth metric as a predictive metric.

The selection process, which began in October 2021, was very rigorous. Out of 285 abstracts received, Forum 78 committee chairs selected 219 papers for publication. During the Forum, the session and technical committee chairs selected the best papers from each of the 21 technical papers for final consideration. Then the Society’s Deputy Technical Directors for Aeromechanics, Vehicle Design, Vehicle Integrity, System Integration, Systems Engineering, and Operations and Product Support winnowed that number down to seven finalists. Following that, the VFS Technical Director and a committee of technical experts reviewed and ranked the papers, and in that ranking, determined that the selected paper was the best of the best. All of the best papers are available for purchase in the Vertical Flight Library & Online Store (http://www.vtol.org/library).

The full list of all Forum 78 best papers:

  • Acoustics: Helicopter Noise Source Separation Using an Order Tracking Filter, by Joel Sundar Rachaprolu and Eric Greenwood, Pennsylvania State University
  • Advanced Vertical Flight: Robotic Hummingbird versus Quadrotor: a Flight Dynamics and Gust Response Comparison, by David Coleman and Moble Benedict, Texas A&M University
  • Aerodynamics: High Speed and Highly Efficient Rotor Blade Design, by Byung-Young Min, Vera Klimchenk, Annie Gao, Alex F. Dunn, Claude G. Matalanis and Brian E. Wake, Sikorsky, a Lockheed Martin Co.
  • Aircraft Design (best overall in Vehicle Design disciplines): Wing Lift Enhancement from Aft Rotor Induced Suction, by Richard Healy and Farhan Gandhi, Rensselaer Polytechnic Institute
  • Avionics & Systems (best overall in Systems Integration disciplines): Evaluation of Flight Control System Architectures for the AH-64, by Bryan C. H. Chu, Gary Klein and Russell Enns, The Boeing Company
  • Crash Safety (best overall in Vehicle Integrity disciplines): Advanced Seat Belt System for Occupant Restraint, by Marv Richards, Safe Inc.
  • Crew Stations & Human Factors: Differential Role of Gravitoinertial Cues for Active and Passive Control in Degraded Visual Environments, by Martine Godfroy-Cooper, U.S. Army DEVCOM AvMC; J.C. Sarrazin, ONERA; E. Bachelder and J. D. Miller, U.S. Army DEVCOM AvMC; and Dr. B. Bardy, Euromov
  • Dynamics: Time-Frequency Analysis of Experimental and Analytical Hub Loads of a Rotor Undergoing a Rotor Speed Change, by Martin K. Sekula, NASA Langley Research Center; and Carl Russell, NASA Ames Research Center
  • Electric VTOL Technical Committee: Fabrication, Testing, and Comparative Analysis of Lithium Sulfur and Lithium-Ion Electrochemistries, by Emily Fisler and Anubhav Datta, University of Maryland
  • Handling Qualities (best overall in Aeromechanics disciplines, and overall Gessow Winner): Toward a UAS Handling Qualities Specification: Development of UAS-Specific MTEs, by Christina M. Ivler, Kate Russell, University of Portland; Anthony Gong, Tom Berger and Mark J.S. Lopez, U.S. Army DEVCOM AvMC
  • Health and Usage Management Systems (best overall in Systems Engineering disciplines): Improving the Performance of Bearing Analysis, by Eric Bechhoefer and Joshua Kethan, GPMS Inc.
  • Manufacturing Tech. & Processing: Manufacturing Innovation for Bell’s Future Factory, by Amber Pike, Bell Textron Inc.
  • Modeling & Simulation: Rotorcraft Pitch-Surge Motion Cueing Requirements for a Simulated Offshore Approach Task, by Josephine Roscoe, Mark D. White, Steven J. Hodge and Gareth D. Padfield, University of Liverpool
  • Operations: Expectations, Test Results, and Lessons Learned, Flight Testing an RF DILR ALE, by Mike Lengyel, Bob Burzynski, Dan Ferrante and Sid McManus, Elbit America
  • Product Support Systems Technology: Scheduled Maintenance Program Development for the Leonardo AW609 Tiltrotor via the Maintenance Review Board Process Utilizing MSG-3, by Titos M. Gosalvez and Nicholas Flynn, Leonardo Helicopters
  • Propulsion: Dynamic Load Analysis of Motion Converter Ball Bearings in a Pericyclic Transmission, by Nick Weinzapfel and Nathan Bolander, Sentient Science; Tanmay Mathur, AgustaWestland; Hans DeSmidt, University of Tennessee; and Edward Smith, Pennsylvania State University
  • Safety: A Structured and Comprehensive Air Vehicle Risk Assessment, by Laurence H. Mutuel, Bell Textron Inc.
  • Structures & Materials: Improved Strain Gage Instrumentation Strategies for Rotorcraft Blade Measurements, by Timothy Davis, U.S. Army DEVCOM AvMC
  • Systems Engineering Tools & Processes: Sikorsky Airframe Full Spectrum Customer/Supplier Collaboration, by Darryl Toni, Sikorsky, a Lockheed Martin Company
  • Test & Evaluation (best overall in Operations & Support disciplines): Automatic Category A Takeoff for H145 – Development and Flight Testing, by Carl Ockier, Dr. Daniel Reber, Marc Salesse-Lavergne and Paul Prévost, Airbus

In addition, the History Committee recognized God’s Machine: The Miracle at Gander, by Paul J. Fardink, US Army (Ret.) as the winner of the Bernard Lindenbaum Best Historical Paper.

This year’s Forum 78 was held in May in Fort Worth, Texas. Next year, the Society’s 79th Annual Forum & Technology Display will be held May 16-18, 2023, in West Palm Beach, Florida. As the Forum 78 Alfred Gessow Best Paper Award winner, Dr. Ivler will present the paper at the 48th Annual European Rotorcraft Forum (ERF) on Sept. 7, 2022, in Winterthur, Switzerland.

Founded in 1943 as the American Helicopter Society, the Vertical Flight Society today is the international organization that advocates, promotes and supports global vertical flight technology and professional development. For nearly 80 years, the Society has provided global leadership for the advancement of vertical flight.

The Vertical Flight Society

2700 Prosperity Ave, Ste. 275, Fairfax, Virginia 22031, USA

phone: 1-703-684-6777; email: staff@vtol.org; website: http://www.vtol.org

Share article on social media or email:

Inheritance of Hope and the Tennessee Credit Union League to Inspire Hope in Nashville


On July 28-31, Inheritance of Hope (IoH) and the Tennessee Credit Union League (TCUL) will welcome young families facing the loss of a parent to Nashville, Tenn., for a Legacy Retreat® – a destination experience where families create lifelong memories and receive tools to navigate the challenges of terminal illness.

The Tennessee Credit Union League was first introduced to Inheritance of Hope through Kim Bohannon, TCUL’s Chief Innovation Officer. Kim and her family attended the Orlando Legacy Retreat® in May 2015 while her late husband faced Multiple System Atrophy (MSA). Impacted by their experience, Kim is dedicated to giving back to families like her own, which has led to a partnership between TCUL and IoH.

In an effort to raise awareness and serve IoH families, TCUL launched the Inspire Hope Credit Union Challenge. Through this initiative, credit unions across Tennessee and beyond have joined together in branch-wide fundraisers to sponsor Inheritance of Hope’s upcoming Legacy Retreat® in Nashville.

“On behalf of the Tennessee Credit Union League, we are honored to be able to help Inheritance of Hope families attend the Legacy Retreat® in Nashville,” said Bohannon. “IoH is intentional about creating memories for families to cherish and about fostering a shared support network. The nonprofit really helps families battling a terminal illness see that they are not alone. So many years later, my children and I still receive communication from IoH as we continue to honor the memory of my late husband and their father.”

During the Legacy Retreat®, families from around the county will make lasting memories together at the Gaylord Opryland Resort, with time spent at SoundWaves waterpark, a Carrie Underwood show at the Grand Ole Opry, opportunities to relax and enjoy accommodations at the beautiful resort and many surprises. Families will also participate in daily group sessions designated for each family member, where they will gain meaningful resources and build

relationships with others in similar situations.

Thanks to TCUL’s partnership, many families will be able to enjoy this memory-making weekend together.

One in 20 children will lose a parent before turning 16. Visit InheritanceOfHope.org to learn how you can help.

About Inheritance of Hope

The Inheritance of Hope (IoH) story began with one young family facing a parent’s terminal illness – a mom and dad with young children looking for resources for their entire family as they all navigated the mom’s illness. Surprisingly, there were none. They decided to create resources for their family and share them with others. In 2007, Deric and Kristen Milligan launched IoH with the mission to inspire hope in young families facing the loss of a parent, and the brand has grown to serve families throughout the U.S.

About Tennessee Credit Union League

Formed in 1934, Tennessee Credit Union League is a 501 (c) (6) non-profit trade association for Tennessee credit unions. Their mission is to promote and support the success and advancement of credit unions in the State of Tennessee by helping them meet their service and structural goals.

Share article on social media or email: